Comparison engine · up to 4 candidates

Compare side-by-side.

Pick up to four peptides. We line up evidence tier, mechanism, half-life, routes, and contraindications. Human data first — never hype.

PT-141Melanotan II

Dimension	PT-141 Bremelanotide	Melanotan II MT-II
Evidence tier	AHuman RCT evidence	CPreclinical only
Intelligence Score™	6.3/ 10 · Moderate	3.6/ 10 · Emerging
Family	α-MSH analogue (MC4)	α-MSH analogue (cyclic)
Half-life	~2.7 h	~33 min
Typical dose	1.75 mg, on-demand	Not recommended — adverse-event risk
Routes	Subcutaneous	Subcutaneous
Tier label	Human RCT	Preclinical only
Mechanism	Melanocortin-4 receptor agonist; central pro-erectile/libido pathway.	Non-selective melanocortin receptor agonist (MC1, MC3, MC4, MC5).
Reported uses	—	—
Contraindications	— Uncontrolled hypertension — Cardiovascular disease	— Pregnancy — Personal/family melanoma — History of moles/dysplastic nevi
Citations	1	1

AHuman RCT evidence

Intelligence Score™: 6.3/ 10 · Moderate
Family: α-MSH analogue (MC4)
Half-life: ~2.7 h
Typical dose: 1.75 mg, on-demand
Routes: Subcutaneous
Tier label: Human RCT
Mechanism: Melanocortin-4 receptor agonist; central pro-erectile/libido pathway.
Reported uses: —
Contraindications: — Uncontrolled hypertension
— Cardiovascular disease
Citations: 1

CPreclinical only

Intelligence Score™: 3.6/ 10 · Emerging
Family: α-MSH analogue (cyclic)
Half-life: ~33 min
Typical dose: Not recommended — adverse-event risk
Routes: Subcutaneous
Tier label: Preclinical only
Mechanism: Non-selective melanocortin receptor agonist (MC1, MC3, MC4, MC5).
Reported uses: —
Contraindications: — Pregnancy
— Personal/family melanoma
— History of moles/dysplastic nevi
Citations: 1

Plain-English summary

Summarize this comparison — evidence depth, mechanism overlap, and the strongest unknowns.

Suggestive, never prescriptive. Discuss with a clinician. How we grade evidence.